Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,074 total articles

Teva to Present at the Goldman Sachs Global Healthcare Conference

Teva to Present at the Goldman Sachs Global Healthcare Conference

Teva Pharmaceutical Industries Ltd. announced that its President and CEO, Richard Francis, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The event will include discussions on the company's business strategy, financial guidance, and ongoing transformation into an innovative biopharmaceutical l…

authID Announces its 2026 Annual Meeting to be Held on July 6, 2026

authID Announces its 2026 Annual Meeting to be Held on July 6, 2026

authID Inc., a Nasdaq-listed provider of biometric identity verification solutions, announces its 2026 Annual Meeting will be held virtually on July 6, 2026. Proposals to be voted on include director elections, auditor ratification, and approval of an equity incentive plan. Shareholders are encouraged to vote by proxy ahead of the webcast meeting.

USCB Financial Holdings, Inc. Names Sergio Garrido Chief Credit Officer; Announces Retirement of William “Bill” Turner

USCB Financial Holdings, Inc. Names Sergio Garrido Chief Credit Officer; Announces Retirement of William “Bill” Turner

USCB Financial Holdings announces the appointment of Sergio E. Garrido as Senior Vice President and Chief Credit Officer of U.S. Century Bank, succeeding William “Bill” Turner upon his retirement. Garrido brings over 15 years of experience, including significant tenure at the bank, ensuring continuity in credit management and reflecting the bank's …

Weatherford Details Value-Driven Case for Redomestication, Encourages Shareholders to Vote FOR Proposal

Weatherford Details Value-Driven Case for Redomestication, Encourages Shareholders to Vote FOR Proposal

Weatherford International plc has filed a definitive proxy statement urging shareholders to approve a proposal redomesticating the company from Ireland back to the United States. The company highlights expected annual cash savings of $20-$30 million starting in 2027, improved shareholder value through simplified corporate structure, enhanced financ…

Hallador Energy Acquires 460 MW of Siemens Turbines for $350 Million, Accelerating Merom Natural Gas Generation Project

Hallador Energy Acquires 460 MW of Siemens Turbines for $350 Million, Accelerating Merom Natural Gas Generation Project

Hallador Energy announced the acquisition of approximately 460 MW of Siemens turbines and ancillary equipment for $350 million, plus additional refurbishment costs, securing critical assets for its Merom natural gas-fired power project. The acquisition significantly reduces development timing risk amid supply constraints, positioning the company to…

XAI Octagon Floating Rate & Alternative Income Trust Declares its Monthly Common Shares Distribution of $0.225 per Share

XAI Octagon Floating Rate & Alternative Income Trust Declares its Monthly Common Shares Distribution of $0.225 per Share

The XAI Octagon Floating Rate & Alternative Income Trust announced its monthly common share distribution of $0.225 per share, unchanged from the previous month. The distribution is payable on July 1, 2026, to shareholders of record as of June 15, 2026. The Trust invests primarily in floating rate credit instruments and structured credit investments…

Praxis Precision Medicines Provides Vormatrigine Program Update

Praxis Precision Medicines Provides Vormatrigine Program Update

Praxis Precision Medicines announced that the Phase 2/3 POWER1 study of vormatrigine in patients with focal onset seizures did not meet its primary endpoint of seizure frequency reduction, though a secondary measure of 50% response rate was met and higher dose showed more pronounced seizure reduction. Vormatrigine was generally well-tolerated with …

Microchip Technology Appoints Mitch Little to Its Board of Directors

Microchip Technology Appoints Mitch Little to Its Board of Directors

Microchip Technology Incorporated announced the appointment of Mitch Little, former senior executive at Microchip, to its Board of Directors effective June 1, 2026. Little brings extensive experience in sales, product management, and leadership, and meets Nasdaq's independence requirements. The company highlighted his role in shaping Microchip's cu…

LXP Industrial Trust Provides Recent Business Activity Update and Increases 2026 Adjusted Company FFO Guidance

LXP Industrial Trust Provides Recent Business Activity Update and Increases 2026 Adjusted Company FFO Guidance

LXP Industrial Trust has reported robust leasing performance, completing 4.6 million square feet of leases year-to-date with significant rental rate increases. The company also acquired a prime 37-acre redevelopment site in Phoenix for $103 million, which is fully leased until 2031 and planned for future industrial development. Following these oper…

California Water Service Earns G480 Platinum Certification for Water-Use Efficiency, Conservation Program

California Water Service Earns G480 Platinum Certification for Water-Use Efficiency, Conservation Program

California Water Service (Cal Water) has earned the prestigious G480 Platinum Certification from the Alliance for Water Efficiency, recognizing its leadership in water-use efficiency and conservation program management under the updated G480-25 standard. This achievement highlights Cal Water's commitment to sustainability, high-quality service, and…

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Minerva Neurosciences has established a Scientific Advisory Board (SAB) composed of leading experts in psychiatry and neuroscience to guide the clinical development of roluperidone, an investigational drug targeting negative symptoms of schizophrenia, and to advise on future pipeline programs. The SAB formation fulfills a prior PIPE financing commi…

Merlin, Inc. To Participate in Upcoming Investor Conferences

Merlin, Inc. To Participate in Upcoming Investor Conferences

Merlin, Inc., an aerospace and defense technology company focused on autonomous flight systems, has announced its management will take part in multiple investor conferences throughout June 2026. The events include the Jefferies Defense Tech Summit, ROTH Capital Partners Annual London Conference, and the Maxim Group Defense Tech Conference. The comp…

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

Fulcrum Therapeutics announced discontinuation of its pociredir program for sickle cell disease after receiving FDA feedback that raised concerns about the risk of secondary malignancies linked to the drug's target, influenced by a related drug's market withdrawal. Despite positive clinical signals, the FDA sees no viable regulatory path forward. F…

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax reported positive Phase 3 ABTECT maintenance trial results for obefazimod, an oral miR-124 enhancer, showing significant clinical remission rates at week 44 in patients with moderately to severely active ulcerative colitis. Both 25 mg and 50 mg doses met primary and all key secondary endpoints with a favorable safety profile. The company pla…